Neuroendocrine Prostate Cancer Market Report Infographic Image

Published : February 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Neuroendocrine Prostate Cancer Market Report 2026

Name: Neuroendocrine Prostate Cancer Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Treatment (Chemotherapy, Hormonal Therapy), By Therapeutics (Immunotherapy, Targeted Therapy), By Disease Stage (Localized Disease, Advanced Disease, Metastatic Disease), By End Users (Hospitals, Oncology Specialty Clinics, Cancer Research Institutes) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Purchase This Report Download Sample PDF

Item added to cart!

Neuroendocrine Prostate Cancer Market Overview

• Neuroendocrine Prostate Cancer market size has reached to $1.05 billion in 2025

• Expected to grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%

• Growth Driver: Increasing Prevalence Of Prostate Cancer Driving The Market Growth Due To Rising Aging Male Population

• Market Trend: Next-Generation Therapeutic Approaches Targeting Treatment-Resistant Tumors

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuroendocrine Prostate Cancer Market?

Neuroendocrine prostate cancer is a rare and aggressive form of prostate cancer characterized by the presence of neuroendocrine cells, which can influence tumor growth and resistance to conventional therapies. The disease may develop de novo or emerge following long-term androgen deprivation therapy in prostate cancer patients. Treatment approaches include chemotherapy, targeted therapy, immunotherapy, and supportive care to manage symptoms and improve patient outcomes.

The main types of neuroendocrine prostate cancer include chemotherapy and hormonal therapy. Chemotherapy refers to the use of cytotoxic drugs to kill or inhibit the growth of cancer cells in the prostate. These treatments are also available as therapeutics including immunotherapy and targeted therapy. They are applied across disease stages including localized disease, advanced disease, and metastatic disease, and are used by end users including hospitals, oncology specialty clinics, and cancer research institutes.

Neuroendocrine Prostate Cancer Market Report bar graph

What Is The Neuroendocrine Prostate Cancer Market Size and Share 2026?

The neuroendocrine prostate cancer market size has grown strongly in recent years. It will grow from $1.05 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rise in prostate cancer diagnosis, long term Hormone Therapy resistance, expansion of oncology drug pipelines, growth of molecular pathology testing, increased cancer center specialization.

What Is The Neuroendocrine Prostate Cancer Market Growth Forecast?

The neuroendocrine prostate cancer market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth of precision oncology adoption, rising biomarker based treatment, expansion of targeted therapies, increased rare cancer research funding, broader genomic testing use. Major trends in the forecast period include biomarker driven patient stratification, combination oncology therapy protocols, advanced molecular diagnostic testing, rare cancer clinical trial expansion, targeted radiopharmaceutical approaches.

Book your 30 minutes free consultation with our research experts

Global Neuroendocrine Prostate Cancer Market Segmentation

1) By Treatment: Chemotherapy; Hormonal Therapy

2) By Therapeutics: Immunotherapy; Targeted Therapy

3) By Disease Stage: Localized Disease; Advanced Disease; Metastatic Disease

4) By End Users: Hospitals; Oncology Specialty Clinics; Cancer Research Institutes

Subsegments:

1) By Chemotherapy: Platinum Based Chemotherapy; Taxane Based Chemotherapy; Combination Chemotherapy; Second Line Chemotherapy

2) By Hormonal Therapy: Androgen Deprivation Therapy; Androgen Receptor Inhibition; Hormone Synthesis Inhibition; Combined Hormonal Therapy

What Is The Driver Of The Neuroendocrine Prostate Cancer Market?

The increasing prevalence of prostate cancer is expected to propel the growth of the neuroendocrine prostate cancer market going forward. Prostate cancer is a malignant tumor that develops in the prostate gland, primarily affecting men over the age of 50. The prevalence of prostate cancer is rising largely due to the growing aging male population, as advancing age is a major risk factor for disease development. Prevalence of prostate cancer supports the growth of neuroendocrine prostate cancer by expanding the overall patient pool, increasing long-term exposure to androgen-deprivation therapies, and consequently raising the likelihood of treatment-induced neuroendocrine differentiation in advanced and castration-resistant disease stages. For instance, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S. federal public health agency, reported that in 2023 there were 255,395 new cases of prostate cancer diagnosed in the United States, and 33,881 men died from the disease. Therefore, increasing prevalence of prostate cancer is driving the growth of the neuroendocrine prostate cancer industry.

Key Players In The Global Neuroendocrine Prostate Cancer Market

Major companies operating in the neuroendocrine prostate cancer market are Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.

Global Neuroendocrine Prostate Cancer Market Trends and Insights

Major companies operating in the neuroendocrine prostate cancer market are focusing on developing innovative drugs such as immune-modulating small-molecule therapies to enhance immune response and improve patient outcomes. Immune-modulating small-molecule therapies are orally administered compounds that stimulate the body’s innate immune system to recognize and attack cancer cells, helping overcome resistance to traditional treatments such as hormone therapy or chemotherapy by enhancing the anti-tumor immune response. For instance, in February 2024, BioXcel Therapeutics, a US-based clinical-stage biopharmaceutical company, received Fast Track Designation from the U.S. Food and Drug Administration for BXCL701, an immune-modulating small-molecule therapy for neuroendocrine prostate cancer. BXCL701 is designed to activate the NLRP3 inflammasome, increase cytokine release, and prime the immune system to target tumor cells, offering a novel approach that complements immune checkpoint inhibitors. The Fast Track Designation is expected to accelerate the clinical development and regulatory review of BXCL701, reflecting its potential to address significant unmet medical needs in aggressive and treatment-resistant prostate cancer.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Neuroendocrine Prostate Cancer Market?

In March 2024, Merck & Co. Inc., a US-based healthcare and biopharmaceutical company, acquired Harpoon Therapeutics, Inc. for an undisclosed amount. With this acquisition, Merck & Co., Inc. aims to broaden and diversify its oncology pipeline by enhancing its portfolio of novel T-cell engagers for advanced cancers. Harpoon Therapeutics Inc. is a US-based biotechnology company that specializes in developing innovative T-cell engager therapies targeting cancers such as small cell lung cancer, neuroendocrine prostate cancer, and multiple myeloma.

Regional Insights

North America was the largest region in the neuroendocrine prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuroendocrine Prostate Cancer Market?

The neuroendocrine prostate cancer market consists of revenues earned by entities by providing services such as advanced diagnostic and pathological testing, molecular and biomarker analysis, oncological consultations, personalized treatment planning, and administration and monitoring of systemic therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine prostate cancer market also includes sales of chemotherapeutic agents, hormone therapy–resistant drugs, radiopharmaceuticals, diagnostic kits and biomarker assays, and supportive oncology medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neuroendocrine Prostate Cancer Market Report 2026?

The neuroendocrine prostate cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine prostate cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Neuroendocrine Prostate Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$1.14 billion
Revenue Forecast In 2035	$1.6 billion
Growth Rate	CAGR of 8.5% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Treatment, Therapeutics, Disease Stage, End Users
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Neuroendocrine Prostate Cancer Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Neuroendocrine Prostate Cancer Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Neuroendocrine Prostate Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Neuroendocrine Prostate Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Biomarker Driven Patient Stratification

4.2.2 Combination Oncology Therapy Protocols

4.2.3 Advanced Molecular Diagnostic Testing

4.2.4 Rare Cancer Clinical Trial Expansion

4.2.5 Targeted Radiopharmaceutical Approaches

5. Neuroendocrine Prostate Cancer Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Oncology Specialty Clinics

5.3 Cancer Research Institutes

5.4 Academic Medical Centers

5.5 Specialty Diagnostic Laboratories

6. Neuroendocrine Prostate Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neuroendocrine Prostate Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Neuroendocrine Prostate Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Neuroendocrine Prostate Cancer Market Size, Comparisons And Growth Rate Analysis

7.3. Global Neuroendocrine Prostate Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Neuroendocrine Prostate Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neuroendocrine Prostate Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neuroendocrine Prostate Cancer Market Segmentation

9.1. Global Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Chemotherapy, Hormonal Therapy

9.2. Global Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Immunotherapy, Targeted Therapy

9.3. Global Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Localized Disease, Advanced Disease, Metastatic Disease

9.4. Global Neuroendocrine Prostate Cancer Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Oncology Specialty Clinics, Cancer Research Institutes, Academic Medical Centers

9.5. Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Platinum Based Chemotherapy, Taxane Based Chemotherapy, Combination Chemotherapy, Second Line Chemotherapy

9.6. Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Androgen Deprivation Therapy, Androgen Receptor Inhibition, Hormone Synthesis Inhibition, Combined Hormonal Therapy

10. Neuroendocrine Prostate Cancer Market Regional And Country Analysis

10.1. Global Neuroendocrine Prostate Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Neuroendocrine Prostate Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neuroendocrine Prostate Cancer Market

11.1. Asia-Pacific Neuroendocrine Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neuroendocrine Prostate Cancer Market

12.1. China Neuroendocrine Prostate Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neuroendocrine Prostate Cancer Market

13.1. India Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neuroendocrine Prostate Cancer Market

14.1. Japan Neuroendocrine Prostate Cancer Market Overview

14.2. Japan Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neuroendocrine Prostate Cancer Market

15.1. Australia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neuroendocrine Prostate Cancer Market

16.1. Indonesia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neuroendocrine Prostate Cancer Market

17.1. South Korea Neuroendocrine Prostate Cancer Market Overview

17.2. South Korea Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neuroendocrine Prostate Cancer Market

18.1. Taiwan Neuroendocrine Prostate Cancer Market Overview

18.2. Taiwan Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neuroendocrine Prostate Cancer Market

19.1. South East Asia Neuroendocrine Prostate Cancer Market Overview

19.2. South East Asia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neuroendocrine Prostate Cancer Market

20.1. Western Europe Neuroendocrine Prostate Cancer Market Overview

20.2. Western Europe Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neuroendocrine Prostate Cancer Market

21.1. UK Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neuroendocrine Prostate Cancer Market

22.1. Germany Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neuroendocrine Prostate Cancer Market

23.1. France Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neuroendocrine Prostate Cancer Market

24.1. Italy Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neuroendocrine Prostate Cancer Market

25.1. Spain Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neuroendocrine Prostate Cancer Market

26.1. Eastern Europe Neuroendocrine Prostate Cancer Market Overview

26.2. Eastern Europe Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neuroendocrine Prostate Cancer Market

27.1. Russia Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neuroendocrine Prostate Cancer Market

28.1. North America Neuroendocrine Prostate Cancer Market Overview

28.2. North America Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neuroendocrine Prostate Cancer Market

29.1. USA Neuroendocrine Prostate Cancer Market Overview

29.2. USA Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neuroendocrine Prostate Cancer Market

30.1. Canada Neuroendocrine Prostate Cancer Market Overview

30.2. Canada Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neuroendocrine Prostate Cancer Market

31.1. South America Neuroendocrine Prostate Cancer Market Overview

31.2. South America Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neuroendocrine Prostate Cancer Market

32.1. Brazil Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neuroendocrine Prostate Cancer Market

33.1. Middle East Neuroendocrine Prostate Cancer Market Overview

33.2. Middle East Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neuroendocrine Prostate Cancer Market

34.1. Africa Neuroendocrine Prostate Cancer Market Overview

34.2. Africa Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Segmentation By Therapeutics, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neuroendocrine Prostate Cancer Market Regulatory and Investment Landscape

36. Neuroendocrine Prostate Cancer Market Competitive Landscape And Company Profiles

36.1. Neuroendocrine Prostate Cancer Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Neuroendocrine Prostate Cancer Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Neuroendocrine Prostate Cancer Market Company Profiles

36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Phanes Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. BioXcel Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Global Neuroendocrine Prostate Cancer Market Competitive Benchmarking And Dashboard

38. Upcoming Startups in the Market

39. Key Mergers And Acquisitions In The Neuroendocrine Prostate Cancer Market

40. Neuroendocrine Prostate Cancer Market High Potential Countries, Segments and Strategies

40.1 Neuroendocrine Prostate Cancer Market In 2030 - Countries Offering Most New Opportunities

40.2 Neuroendocrine Prostate Cancer Market In 2030 - Segments Offering Most New Opportunities

40.3 Neuroendocrine Prostate Cancer Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Neuroendocrine Prostate Cancer Market, Overview Of Key Products - Product Examples

Table 2: Global Neuroendocrine Prostate Cancer Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Neuroendocrine Prostate Cancer Market, Supply Chain Analysis

Table 4: Global Neuroendocrine Prostate Cancer Market, Major Raw Material Providers

Table 5: Global Neuroendocrine Prostate Cancer Market, Major Resource Providers

Table 6: Global Neuroendocrine Prostate Cancer Market, Major Manufacturers (Suppliers)

Table 7: Global Neuroendocrine Prostate Cancer Market, Major Distributors And Channel Partners

Table 8: Global Neuroendocrine Prostate Cancer Market, Key Technologies & Future Trends

Table 9: Global Neuroendocrine Prostate Cancer Market, Major Trends

Table 10: Global Neuroendocrine Prostate Cancer Market, Major End Users

Table 11: Global Neuroendocrine Prostate Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Neuroendocrine Prostate Cancer Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Neuroendocrine Prostate Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Neuroendocrine Prostate Cancer Market - TAM, US$ Billion, 2025

Table 15: Global Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Neuroendocrine Prostate Cancer Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Neuroendocrine Prostate Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Neuroendocrine Prostate Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Asia-Pacific, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Asia-Pacific, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: China, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: China, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: India, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: India, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: Japan, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Japan, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Australia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Australia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Indonesia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Indonesia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: South Korea, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: South Korea, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: Taiwan, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Taiwan, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: South East Asia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: South East Asia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: Western Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Western Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: UK, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: UK, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: Germany, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: Germany, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: France, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: France, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Italy, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Italy, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Spain, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Spain, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Eastern Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Eastern Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Russia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Russia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: North America, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: North America, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: USA, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: USA, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: Canada, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: Canada, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: South America, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: South America, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: Brazil, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Brazil, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Middle East, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Middle East, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Africa, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Africa, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Global Neuroendocrine Prostate Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 96: Global Neuroendocrine Prostate Cancer Market - Company Scoring Matrix

Table 97: Upcoming Startups

Table 98: Novartis AG Financial Performance

Table 99: Amgen Inc. Financial Performance

Table 100: Phanes Therapeutics Inc. Financial Performance

Table 101: BioXcel Therapeutics Inc. Financial Performance

Table 102: Global Neuroendocrine Prostate Cancer Market, Competitive Benchmarking (In USD Billions)

Table 103: Global Neuroendocrine Prostate Cancer Market, Competitive Dashboard

Table 104: Global Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 105: Global, Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), Segmentation By Treatment, 2025 – 2030

Table 106: Global, Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), Segmentation By Therapeutics, 2025 – 2030

Table 107: Global, Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), Segmentation By Disease Stage, 2025 – 2030

List Of Figures

Figure 1: Global Neuroendocrine Prostate Cancer Market, Overview Of Key Products - Product Examples

Figure 2: Global Neuroendocrine Prostate Cancer Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Neuroendocrine Prostate Cancer Market, Supply Chain Analysis

Figure 4: Global Neuroendocrine Prostate Cancer Market, Major Raw Material Providers

Figure 5: Global Neuroendocrine Prostate Cancer Market, Major Resource Providers

Figure 6: Global Neuroendocrine Prostate Cancer Market, Major Manufacturers (Suppliers)

Figure 7: Global Neuroendocrine Prostate Cancer Market, Major Distributors And Channel Partners

Figure 8: Global Neuroendocrine Prostate Cancer Market, Key Technologies & Future Trends

Figure 9: Global Neuroendocrine Prostate Cancer Market, Major Trends

Figure 10: Global Neuroendocrine Prostate Cancer Market, Major End Users

Figure 11: Global Neuroendocrine Prostate Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Neuroendocrine Prostate Cancer Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Neuroendocrine Prostate Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Neuroendocrine Prostate Cancer Market - TAM, US$ Billion, 2025

Figure 15: Global Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Neuroendocrine Prostate Cancer Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Neuroendocrine Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Neuroendocrine Prostate Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Neuroendocrine Prostate Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Asia-Pacific, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Asia-Pacific, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: China, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: China, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: India, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: India, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: Japan, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Japan, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Australia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Australia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Indonesia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Indonesia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: South Korea, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: South Korea, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: Taiwan, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Taiwan, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: South East Asia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: South East Asia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: Western Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Western Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: UK, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: UK, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: Germany, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: Germany, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: France, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: France, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Italy, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Italy, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Spain, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Spain, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Eastern Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Eastern Europe, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Russia, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Russia, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: North America, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: North America, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: USA, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: USA, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: Canada, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: Canada, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: South America, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: South America, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: Brazil, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Brazil, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Middle East, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Middle East, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Africa, Neuroendocrine Prostate Cancer Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Neuroendocrine Prostate Cancer Market, Segmentation By Therapeutics, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Africa, Neuroendocrine Prostate Cancer Market, Segmentation By Disease Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Global Neuroendocrine Prostate Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 96: Global Neuroendocrine Prostate Cancer Market - Company Scoring Matrix

Figure 97: Upcoming Startups

Figure 98: Novartis AG Financial Performance

Figure 99: Amgen Inc. Financial Performance

Figure 100: Phanes Therapeutics Inc. Financial Performance

Figure 101: BioXcel Therapeutics Inc. Financial Performance

Figure 102: Global Neuroendocrine Prostate Cancer Market, Competitive Benchmarking (In USD Billions)

Figure 103: Global Neuroendocrine Prostate Cancer Market, Competitive Dashboard

Figure 104: Global Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 105: Global, Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), Segmentation By Treatment, 2025 – 2030

Figure 106: Global, Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), Segmentation By Therapeutics, 2025 – 2030

Figure 107: Global, Neuroendocrine Prostate Cancer Market Size Gain ($ Billion), Segmentation By Disease Stage, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Prostate Cancer Drugs Market Report 2026 - Global Outlook – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer), By Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), B...

Equipment Finance Service Market Report 2026 - Global Outlook – By Type (Equipment Loan, Equipment Lease, Other Types), By Provider (Banks, Non-Banking Financial Company (NBFC), Other Providers), By Application (Transpor...

Drugs For Benign Prostatic hypertrophy Market Report 2026 - Global Outlook – By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types), By Distribution Channel (Hospital Pharmacies,...

Blood Plasma Derivatives Market Report 2026 - Global Outlook – By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Other Types), By Application (Hemophilia, Hypogammaglobulinemia, Immunodefici...

Bladder Cancer Drugs Market Report 2026 - Global Outlook – By Type (Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer), By Application (Low-Grade Tumors, High-Grade Tumors), By Distribution Channel (Hosp...

Marine Audio Market Report 2026 - Global Outlook – By Product (Speaker, Subwoofer, Stereo Receiver, Amplifier), By Boat Type (Inboard, Outboard, Sterndrive, Other Boats), By Technology (Wired, Wireless), By Sales (Origin...

Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Report 2026 - Global Outlook – By Product (Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants), By Procedur...

Frequently Asked Questions

How big is the Neuroendocrine Prostate Cancer Market?

The Neuroendocrine Prostate Cancer market was valued at $1.05 billion in 2025, increased to $1.14 billion in 2026, and is projected to reach $1.6 billion by 2030.

What is the Neuroendocrine Prostate Cancer market growth?

The global Neuroendocrine Prostate Cancer market is expected to grow at a CAGR of 8.7% from 2026 to 2035 to reach $1.6 billion by 2035.

Who are the key players in Neuroendocrine Prostate Cancer market?

Some Key Players in the Neuroendocrine Prostate Cancer market Include, Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc. .

What is the anticipated growth trend for the Neuroendocrine Prostate Cancer market?

Major trend in this market includes: Next-Generation Therapeutic Approaches Targeting Treatment-Resistant Tumors. For further insights on this market. request a sample here

Which region has the most growth potential in the Neuroendocrine Prostate Cancer market?

North America was the largest region in the neuroendocrine prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.